View Item 

Show simple item record

Concurrent Administration of Sirolimus and Voriconazole: A Pilot Study Assessing Safety and Approaches to Appropriate Management
dc.contributor.authorSurowiec, Dorothyen_US
dc.contributor.authorDePestel, Daryl D.en_US
dc.contributor.authorCarver, Peggy L.en_US
dc.date.accessioned2012-03-16T15:55:13Z
dc.date.available2012-03-16T15:55:13Z
dc.date.issued2008-06en_US
dc.identifier.citationSurowiec, Dorothy; DePestel, Daryl D.; Carver, Peggy L. (2008). "Concurrent Administration of Sirolimus and Voriconazole: A Pilot Study Assessing Safety and Approaches to Appropriate Management." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28(6). <http://hdl.handle.net/2027.42/90136>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90136
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherDrug Interactionen_US
dc.subject.otherTransplantationen_US
dc.subject.otherVoriconazoleen_US
dc.subject.otherSirolimusen_US
dc.subject.otherAspergillosisen_US
dc.titleConcurrent Administration of Sirolimus and Voriconazole: A Pilot Study Assessing Safety and Approaches to Appropriate Managementen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacy Services, University of Michigan Health System, and the Department of Clinical Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan.en_US
dc.identifier.pmid18503400en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90136/1/phco.28.6.719.pdf
dc.identifier.doi10.1592/phco.28.6.719en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceMathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc 2004; 36: 2708 – 9.en_US
dc.identifier.citedreferenceDe La Rosa GR, Champlin RE, Kontoyiannis DP. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transpl Infect Dis 2002; 4: 3 – 9.en_US
dc.identifier.citedreferenceStrasfeld L, Weinstock DM. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther 2006; 4: 457 – 68.en_US
dc.identifier.citedreferenceSambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis [online exclusive article]. Am J Med 2006; 119: 527.e17 – 24. Available from http:dx.doi.org10.1016j.amjmed.2005.11.028.en_US
dc.identifier.citedreferencePerfect JR, Marr KA, Walsh TJ,. Voriconazole treatment for less‐common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122 – 31.en_US
dc.identifier.citedreferenceDenning DW, Ribaud P, Milpied N,. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563 – 71.en_US
dc.identifier.citedreferenceHerbrecht R, Denning DW, Patterson TF,. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408 – 15.en_US
dc.identifier.citedreferencePfizer Inc. Vfend (voriconazole) package insert. New York, NY; 2003.en_US
dc.identifier.citedreferenceSaad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730 – 44.en_US
dc.identifier.citedreferenceWyeth Pharmaceuticals Inc. Rapamune (sirolimus) package insert. Philadelphia, PA; 2006.en_US
dc.identifier.citedreferencePerez‐Simon JA, Sanchez‐Abarca I, Diez‐Campelo M, Caballero D, Miguel San J.. Chronic graft‐versus‐host disease: pathogenesis and clinical management. Drugs 2006; 66: 1041 – 57.en_US
dc.identifier.citedreferenceMehrabi A, Fonouni H, Kashfi A,. The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant 2006; 20: 30 – 43.en_US
dc.identifier.citedreferenceLischke R, Simonek J, Matousovic K,. Initial single‐center experience with sirolimus after lung transplantation. Transplant Proc 2006; 38: 3006 – 11.en_US
dc.identifier.citedreferenceAranda‐Dios A, Lage E, Sobrino JM,. Sirolimus experience in heart transplantation. Transplant Proc 2006; 38: 2547 – 9.en_US
dc.identifier.citedreferenceMarty FM, Lowry CM, Cutler CS,. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 552 – 9.en_US
dc.identifier.citedreferenceSadaba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004; 36: 3226 – 8.en_US
dc.identifier.citedreferenceSaid A, Garnick JJ, Dieterle N, Peres E, Abidi MH, Ibrahim RB. Sirolimus‐itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 2006; 26: 289 – 95.en_US
dc.identifier.citedreferenceVenkatakrishnan K, Von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 2001; 41: 1149 – 79.en_US
dc.identifier.citedreferenceAnnesley TM, Clayton L. Simple extraction protocol for analysis of immunosuppressant drugs in whole blood. Clin Chem 2004; 50: 1845 – 8.en_US
dc.identifier.citedreferenceHolt DW, Denny K, Lee TD, Johnston A. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. Transplant Proc 2003; 35: S157 – 61.en_US
dc.identifier.citedreferenceStenton SB, Partovi N, Ensom MH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet 2005; 44: 769 – 86.en_US
dc.identifier.citedreferencePauli‐Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P‐glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 551 – 7.en_US
dc.identifier.citedreferenceMcNeil MM, Nash SL, Hajjeh RA,. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 2001; 33: 641 – 7.en_US
dc.identifier.citedreferenceMarik PE. Fungal infections in solid organ transplantation. Expert Opin Pharmacother 2006; 7: 297 – 305.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.28.6.719.pdf
Size:
104.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.